To compare cardiovascular outcomes in older adults with subclinical hypothyroidism (SCH) who were either prescribed or not prescribed levothyroxine (LT4), highlighting the clinical significance of this comparison.
Key Findings:
LT4 therapy showed a protective effect against cardiovascular events (HR: 0.91; 95% CI, 0.87-0.97; P < .001).
LT4 therapy increased the risk of bone events (HR: 1.21; 95% CI, 1.14-1.28; P < .001) and all-cause mortality (HR: 1.17; 95% CI, 1.13-1.22; P < .001).
The study suggests a trade-off between cardiovascular benefits and risks to bone health and mortality.
Interpretation:
LT4 therapy in older adults with SCH may reduce cardiovascular risk but is associated with increased risks of bone health issues and mortality, necessitating careful consideration in treatment decisions and discussions with patients.
Limitations:
Retrospective design may introduce biases, such as selection bias.
Potential confounding factors, such as comorbidities and medication use, were not fully controlled for.
Conclusion:
The findings highlight the need for a balanced approach when considering LT4 therapy in older patients with SCH, weighing cardiovascular benefits against potential harms, and emphasizing the importance of individualized treatment decisions.
